<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813046</url>
  </required_header>
  <id_info>
    <org_study_id>BTT-gpASIT002</org_study_id>
    <secondary_id>EudraCT 2008-006368-12</secondary_id>
    <nct_id>NCT00813046</nct_id>
  </id_info>
  <brief_title>Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis</brief_title>
  <official_title>Preliminary Assessment of the Short Term Clinical Tolerability and Safety of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioTech Tools S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioTech Tools S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the oral administration of grass pollen&#xD;
      peptides to treat allergic rhinitis is safe and well tolerated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the clinical tolerability and safety of the treatment by looking at the absence of immediate allergic reaction.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>vital signs clinical laboratory evaluations adverse events general physical status</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Seasonal Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>gpASIT+TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gpASIT+TM</intervention_name>
    <description>oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days</description>
    <arm_group_label>gpASIT+TM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 50 years&#xD;
&#xD;
          -  The subjects are in good physical and mental health according to his/her medical&#xD;
             history, vital signs, and clinical status&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females&#xD;
&#xD;
          -  A history of seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen&#xD;
             season during at least the last two years&#xD;
&#xD;
          -  A positive skin prick test to grass-pollen mixture&#xD;
&#xD;
          -  Specific IgE against grass pollen (RAST class 2 or IgE &gt; 0.7 kU/l)&#xD;
&#xD;
          -  Asymptomatic to perennial inhalant allergens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with current or past immunotherapy for SAR&#xD;
&#xD;
          -  Subjects requiring controller medication against asthma (bronchodilator nebulised&#xD;
             drugs or local or systemic corticosteroids)&#xD;
&#xD;
          -  Documented evidence of acute or significant chronic sinusitis (as determined by&#xD;
             individual investigator)&#xD;
&#xD;
          -  Subjects with a history of food allergy and consecutive anaphylaxis&#xD;
&#xD;
          -  Subjects with a history of hepatic or renal disease&#xD;
&#xD;
          -  Subject with malignant disease, autoimmune disease&#xD;
&#xD;
          -  Female subjects who are pregnant, lactating, or of child-bearing potential and not&#xD;
             protected from pregnancy by a sufficiently reliable method (OCs, IUD).&#xD;
&#xD;
          -  Females unable to bear children must have documentation of such (i.e. tubal ligation,&#xD;
             hysterectomy, or post menopausal [defined as a minimum of one year since the last&#xD;
             menstrual period])&#xD;
&#xD;
          -  Any chronic disease, which may impair the subject's ability to participate in the&#xD;
             trial (i.e. severe congestive heart failure, active gastric or duodenal ulcer,&#xD;
             uncontrolled diabetes mellitus, etc…)&#xD;
&#xD;
          -  Subjects with clinically relevant abnormal QTc intervals of the ECG : QTc &gt; 450 ms for&#xD;
             man and &gt; 470 ms for women&#xD;
&#xD;
          -  Subjects requiring beta-blockers medication&#xD;
&#xD;
          -  Chronic use of concomitant medications that would affect assessment of the&#xD;
             effectiveness of the study medication (e.g. tricyclic antidepressants)&#xD;
&#xD;
          -  Subject with febrile illness (&gt; 37.5°C, oral)&#xD;
&#xD;
          -  A known positive serology for HIV-1/2, HBs antigen or anti-HCV antibodies&#xD;
&#xD;
          -  The subject is immunocompromised by medication or illness, has received a vaccine,&#xD;
             corticoids or immunosuppressive medications within 1 month before study entry&#xD;
&#xD;
          -  Receipt of blood or a blood derivative in the past 6 months preceding study entry&#xD;
&#xD;
          -  Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs&#xD;
             within 4 weeks preceding the study, any consumption of corticoids (oral, topic or&#xD;
             nasal) or of anti-histaminic drugs within 1 week preceding the study&#xD;
&#xD;
          -  Use of long-acting antihistamines&#xD;
&#xD;
          -  Any condition which could be incompatible with protocol understanding and compliance&#xD;
&#xD;
          -  Subjects who have forfeited their freedom by administrative or legal award or who are&#xD;
             under guardianship,&#xD;
&#xD;
          -  Participation in another clinical trial and/or treatment with an experimental drug&#xD;
             within 1 month of study start&#xD;
&#xD;
          -  A history of hypersensitivity to the excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital University Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

